PCMO Initiative Gathers Strength - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PCMO Initiative Gathers Strength
A review of current efforts within PDA's Paradigm Change in Manufacturing Operations initiative.


Pharmaceutical Technology
Volume 35, Issue 4, pp. 80-82


Richard Levy
In June 2008, the Parenteral Drug Association (PDA) Board of Directors approved the development of a new initiative called the Paradigm Change in Manufacturing Operations, or PCMOSM for short. The goal of the PCMO program of activities is to provide an overarching framework for topics which will become the subject matter of future PDA technical reports and other documents and training events.

Background

By virtue of the PCMO governance, there is a steering committee made up of PDA Advisory Board members and as well as a number of task forces. As part of the PCMO governance process, each topic is prioritized to maximize the value of the expected deliverables to pharmaceutical manufacturers of investigational medicinal products (IMPs) and commercial products.


Table I: PCMO project portfolio.
The steering committee has developed a portfolio of current deliverables (see Table I) to facilitate the implementation of the guidelines from the International Conference on Harmonization (ICH) guidelines Q8 Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System.

Generally on PCMO project teams, an effort is made to incorporate membership from small, local to large, global pharmaceutical and biotechnology companies, technology enablers, and, in some cases, regulators from the US and Europe. There is an understanding among participants that PDA is working toward the common objective of delivering output that embodies the best experiences of our members and, in so doing, creating consensus-based approaches that are not only grounded on ICH principles, but also are pragmatic and scalable such that they can be implemented by any size of company.

PCMO projects

The PCMO portfolio of projects follows the product life-cycle concept and has the following broad strategic intent:

  • Enable an innovative environment for continual improvement of products and systems
  • Integrate science and technology into manufacturing practice
  • Enhance manufacturing process robustness, risk-based decision-making and knowledge management
  • Foster communication among industry and regulatory authorities.

Accordingly, PCMO projects have been grouped into four broad categories: life-cycle approach, quality systems, process management, and quality risk management. These categories are also consistent with ICH guidelines and with the focus of the majority of PDA technical reports and ongoing projects. There are currently 19 PCMO projects in progress (see Table I). Additional projects will be added as necessary to satisfy the needs of the industry as recognized by PDA membership and approved by its Advisory Boards.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here